Comparison between second generation HydroSoft coils and bare platinum coils for the treatment of large intracranial aneurysms.
Hydrocoils
Large aneurysms
cerebral aneurysm
Journal
Interventional neuroradiology : journal of peritherapeutic neuroradiology, surgical procedures and related neurosciences
ISSN: 2385-2011
Titre abrégé: Interv Neuroradiol
Pays: United States
ID NLM: 9602695
Informations de publication
Date de publication:
Jun 2023
Jun 2023
Historique:
medline:
12
6
2023
pubmed:
24
3
2022
entrez:
23
3
2022
Statut:
ppublish
Résumé
The development of HydroSoft coils (HSC) aims to reduce the high recurrence and retreatment rates observed in large brain aneurysms by improving primary brain aneurysm filling and thus occlusion efficacy. We compared clinical and angiographic effectiveness of bare platinum coils (BPC) versus second generation HSC for large intracranial aneurysms at our center. We included 61 large aneurysms between 2015 and 2018, 29 embolized primarily using HSC and 32 treated with BPC. The aneurysm occlusion rates were assessed after 3 and 12 months with an MRI scan and at 6 moths with a control digital subtraction angiography (DSA) using the Raymond-Roy occlusion classification (RROC). Clinical outcomes were evaluated using the modified ranking scale (mRS). The observed immediate occlusion rate was slightly better in the BPC group, however, this group had a significant increase of progressive reperfusion at all imaging follow-up. Contrarily, the rate of complete occlusion increased significantly in the HSC group, starting from the 6 and 12-months follow-up. 7 aneurysms (11.4%) were re-treated (15.6% BPC and 6.9% HSC). The 6 and 12-months clinical data showed mRS score 0-1 in 96.7% of patients. In our single-center experience, the second generation HydroSoft coils were shown to be safe and effective for endovascular treatment of large intracranial aneurysms with encouraging clinical and angiographic results, also for ruptured aneurysms. Even if the validity is limited due to our small cohort size, HSC showed a significantly lower rate of recurrence at mid-term follow-up when compared to BPC.
Sections du résumé
BACKGROUND
BACKGROUND
The development of HydroSoft coils (HSC) aims to reduce the high recurrence and retreatment rates observed in large brain aneurysms by improving primary brain aneurysm filling and thus occlusion efficacy. We compared clinical and angiographic effectiveness of bare platinum coils (BPC) versus second generation HSC for large intracranial aneurysms at our center.
METHODS
METHODS
We included 61 large aneurysms between 2015 and 2018, 29 embolized primarily using HSC and 32 treated with BPC. The aneurysm occlusion rates were assessed after 3 and 12 months with an MRI scan and at 6 moths with a control digital subtraction angiography (DSA) using the Raymond-Roy occlusion classification (RROC). Clinical outcomes were evaluated using the modified ranking scale (mRS).
RESULTS
RESULTS
The observed immediate occlusion rate was slightly better in the BPC group, however, this group had a significant increase of progressive reperfusion at all imaging follow-up. Contrarily, the rate of complete occlusion increased significantly in the HSC group, starting from the 6 and 12-months follow-up. 7 aneurysms (11.4%) were re-treated (15.6% BPC and 6.9% HSC). The 6 and 12-months clinical data showed mRS score 0-1 in 96.7% of patients.
CONCLUSIONS
CONCLUSIONS
In our single-center experience, the second generation HydroSoft coils were shown to be safe and effective for endovascular treatment of large intracranial aneurysms with encouraging clinical and angiographic results, also for ruptured aneurysms. Even if the validity is limited due to our small cohort size, HSC showed a significantly lower rate of recurrence at mid-term follow-up when compared to BPC.
Identifiants
pubmed: 35317639
doi: 10.1177/15910199221088711
pmc: PMC10369119
doi:
Substances chimiques
Platinum
49DFR088MY
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
321-326Références
Eur J Radiol. 2015 Feb;84(2):261-5
pubmed: 25480678
BMC Neurol. 2018 Oct 5;18(1):167
pubmed: 30290784
Lancet. 2011 May 14;377(9778):1655-62
pubmed: 21571149
Neurol Med Chir (Tokyo). 2006 Aug;46(8):379-84; discussion 384-6
pubmed: 16936458
AJNR Am J Neuroradiol. 2009 Feb;30(2):219-26
pubmed: 18842754
AJNR Am J Neuroradiol. 2014 May;35(5):935-42
pubmed: 24481333
Neuroradiology. 2015 Jun;57(6):599-604
pubmed: 25724881
Neuroradiology. 2016 Aug;58(8):777-86
pubmed: 27137926
Stroke. 2007 Mar;38(3):1091-6
pubmed: 17272767
Eur J Radiol. 2015 Oct;84(10):1954-63
pubmed: 26163427
Stroke. 2001 Sep;32(9):1998-2004
pubmed: 11546888
AJNR Am J Neuroradiol. 2015 Jun;36(6):1136-41
pubmed: 25767183
AJNR Am J Neuroradiol. 2017 Mar;38(3):432-441
pubmed: 28082261
AJNR Am J Neuroradiol. 2014 Sep;35(9):1667-76
pubmed: 24948508
Neuroradiology. 2018 Oct;60(10):1075-1084
pubmed: 30120516
Stroke. 2012 Oct;43(10):2544-50
pubmed: 22836352
J Neurosurg. 1991 Jul;75(1):1-7
pubmed: 2045891
AJNR Am J Neuroradiol. 2010 May;31(5):907-11
pubmed: 20075090
Stroke. 2008 Sep;39(9):2497-504
pubmed: 18617659
AJNR Am J Neuroradiol. 2015 Sep;36(9):1689-94
pubmed: 26228887
AJNR Am J Neuroradiol. 2011 Oct;32(9):1756-61
pubmed: 21920861
Interv Neuroradiol. 2008 Mar 30;14(1):73-83
pubmed: 20557789